Nuclera’s nanodisc panel includes a GPCR screen kit and scale-up reagents, including 8 nanodisc combinations, comprised of 2 ...

Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...

Structure Therapeutics (NasdaqGM:GPCR) reported positive topline Phase 2 results for its oral GLP-1 receptor agonist ...

Commercial sales and marketing agreement enhances 3RnD’s mechanistic toxicity screening panel, and expands the reach of ...

Structure Therapeutics IncGPCR shares are up on Wednesday, probably in reaction to the U.S. Food and Drug Administration (FDA ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...

G protein–coupled receptors (GPCRs) are versatile molecular machines that regulate the majority of physiological responses to chemically diverse hormones and neurotransmitters. Recent breakthroughs in ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early ...

G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...